ALGORAE PHARMACEUTICALS LIMITED - Announcements

Market Cap $18.56M Add to my watchlist

Healthcare Biotechnology

Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an... Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The Company is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

1AI	Response to ASX Aware Query	PRICE SENSITIVE	04/12/13	155.84KB	Share
1AI	NTCELL clinical trial - Further patients approved	PRICE SENSITIVE	25/11/13	94.64KB	Share
1AI	Results of Annual General Meeting		19/11/13	25.19KB	Share
1AI	Managing Director's Presentation to AGM		19/11/13	1.73MB	Share
1AI	Chairman's Address to Shareholders		19/11/13	149.37KB	Share
1AI	Saftey and efficacy findings of DIA 09 study of DIABECELL	PRICE SENSITIVE	01/11/13	291.91KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/13	493.4KB	Share
1AI	Australia Biotech Invest 2013		28/10/13	1.42MB	Share
1AI	Annual Report to shareholders		15/10/13	3.68MB	Share
1AI	Notice of Annual General Meeting/Proxy Form		15/10/13	96.2KB	Share
1AI	First patient successfully implanted with NTCELL	PRICE SENSITIVE	20/09/13	148.65KB	Share
1AI	Publication of pre-clinical trial of NTCELL in Parkinson's	PRICE SENSITIVE	16/09/13	27.62KB	Share
1AI	Appendix 4E and Financial Statements	PRICE SENSITIVE	30/08/13	648.48KB	Share
1AI	LCT Announces Change in Regulatory Strategy		29/08/13	34.2KB	Share
1AI	Preliminary Internal Review of Dia12 Study	PRICE SENSITIVE	27/08/13	59.15KB	Share
1AI	Change of Director's Interest Notice		01/08/13	68.56KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/13	114.03KB	Share
1AI	Change of Share Registry		08/07/13	27.91KB	Share
1AI	Change of Director's Interest Notice		29/05/13	69.91KB	Share
1AI	Open Briefing LCT Clinical Trials Update		09/05/13	153.52KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/13	118.77KB	Share
1AI	CEO on Strategy - Audio Interview		21/03/13	98.84KB	Share
1AI	Open Briefing - CEO on Strategy		21/03/13	274.96KB	Share
1AI	Living Cell Technologies Awarded NZBIO Company of the Year		20/03/13	171.27KB	Share
1AI	Announcement on Half-Year Report		27/02/13	28.51KB	Share
1AI	Appendix 4D and Half-Year Accounts	PRICE SENSITIVE	27/02/13	223.86KB	Share
1AI	Change of Director's Interest Notice		12/02/13	68.61KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/13	66.79KB	Share
1AI	Change of Director's Interest Notice		24/01/13	33.32KB	Share
1AI	Open Briefing interview with MD and CEO Andrea Grant		17/12/12	238.76KB	Share
1AI	LCT & Otsuka to co-develop NTCELL for Parkinson's Disease	PRICE SENSITIVE	17/12/12	119.44KB	Share
1AI	LCT appoints Chief Science and Medical Officer		10/12/12	46.6KB	Share
1AI	LCT starts DIABECELL Phase IIb trial in Argentina		22/11/12	44.04KB	Share
1AI	Strong interim results in Argentinian DIABECELL trial	PRICE SENSITIVE	22/11/12	50.37KB	Share
1AI	Alteration to issued capital		20/11/12	76.79KB	Share
1AI	Initial Director's Interest Notice		19/11/12	28.43KB	Share
1AI	Results of 2012 Annual General Meeting		16/11/12	27.38KB	Share
1AI	AGM Presentation		16/11/12	822.76KB	Share
1AI	Chairman's Address to the 2012 Annual General Meeting		16/11/12	39.99KB	Share
1AI	LCT CEO Dr Andrea Grant appointed Managing Director	PRICE SENSITIVE	16/11/12	41.42KB	Share
1AI	Ethical approval for LCT's NTCELL Phase I trial	PRICE SENSITIVE	16/11/12	40.08KB	Share
1AI	Change of Director's Interest Notice		05/11/12	68.68KB	Share
1AI	Six reasons to invest in LCT		02/11/12	3.88MB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/12	98.21KB	Share
1AI	Annual Report to shareholders		15/10/12	3.11MB	Share
1AI	Notice of Annual General Meeting/Proxy Form		15/10/12	91.73KB	Share
1AI	Authorisation of Ph1 trial of NTCell in Parkinsons Disease	PRICE SENSITIVE	04/10/12	25.74KB	Share
1AI	Form 492		03/10/12	82.16KB	Share
1AI	Change of Director's Interest Notice		28/09/12	68.57KB	Share
1AI	LCT announces positive DIABECELL Phase I/IIa trial	PRICE SENSITIVE	26/09/12	1.83MB	Share
1AI	Preliminary Final Report for the year ended 30 June 2012	PRICE SENSITIVE	29/08/12	758.29KB	Share
1AI	Change of Director's Interest Notice		17/08/12	68.71KB	Share
1AI	Change of Director's Interest Notice		06/08/12	67.23KB	Share
1AI	Change of Director's Interest Notice		24/07/12	68.59KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	23/07/12	100.63KB	Share
1AI	Change of Director's Interest Notice		06/06/12	67.04KB	Share
1AI	LCT restructures for next stage of growth		01/06/12	202.53KB	Share
1AI	LCT's DIABECELL trial extension approved	PRICE SENSITIVE	17/05/12	42.18KB	Share
1AI	Change of Director's Interest Notice		04/05/12	67.68KB	Share
1AI	Cleansing Statement		03/05/12	20.22KB	Share
1AI	Appendix 3B		03/05/12	68.75KB	Share
1AI	LCT's Share Purchase Plan successful		01/05/12	25.85KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	56.65KB	Share
1AI	Dr Barry Snow to lead Parkinson's trial for LCT		17/04/12	32.69KB	Share
1AI	Share Purchase Plan documents mailed to Shareholders		30/03/12	119.8KB	Share
1AI	LCT Presents Novel Parkinson's Disease Treatment Results	PRICE SENSITIVE	21/03/12	27.76KB	Share
1AI	LCT announces Share Purchase Plan	PRICE SENSITIVE	20/03/12	30.32KB	Share
1AI	LCT granted E.U. Patent for tissue engineering	PRICE SENSITIVE	28/02/12	26.18KB	Share
1AI	LCT completes pre-clinical studies of NTCELL in Parkinson's	PRICE SENSITIVE	28/02/12	27.51KB	Share
1AI	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/12	715.61KB	Share
1AI	Price query response	PRICE SENSITIVE	16/02/12	61.79KB	Share
1AI	LCT granted USA Patent for Auckland Island Pigs	PRICE SENSITIVE	02/02/12	27.94KB	Share
1AI	Change in substantial holding		30/01/12	433.11KB	Share
1AI	Becoming a substantial holder		30/01/12	431.98KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	27/01/12	64.43KB	Share
1AI	LCT appoints Chief Executive	PRICE SENSITIVE	28/12/11	25.37KB	Share
1AI	Change of Director's Interest Notice		13/12/11	69.49KB	Share
1AI	Change of Director's Interest Notice		13/12/11	69.25KB	Share
1AI	Change of Director's Interest Notice		13/12/11	69.17KB	Share
1AI	Change of Director's Interest Notice		05/12/11	67.29KB	Share
1AI	Amended AGM Poll Result		30/11/11	29.23KB	Share
1AI	Results of the 2011 Annual General Meeting		28/11/11	50.74KB	Share
1AI	CEO's Presentation to the 2011 AGM		28/11/11	137.78KB	Share
1AI	Chairmans Address to the 2011 AGM		28/11/11	53.96KB	Share
1AI	Change of Director's Interest Notice		24/11/11	68.66KB	Share
1AI	Change of Director's Interest Notice		18/11/11	67.22KB	Share
1AI	Change of Director's Interest Notice		04/11/11	68.53KB	Share
1AI	Settlement of $A50 million JV to commercialise DIABECELL	PRICE SENSITIVE	02/11/11	78.08KB	Share
1AI	Annual Report to shareholders		28/10/11	3.11MB	Share
1AI	Notice of Annual General Meeting/Proxy Form		28/10/11	139.69KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/11	368.17KB	Share
1AI	Otsuka commits $A25 million to JV with LCT	PRICE SENSITIVE	19/10/11	36.51KB	Share
1AI	Cleansing Statement		11/10/11	20.82KB	Share
1AI	Appendix 3B		11/10/11	70.95KB	Share
1AI	Research collaboration with Centocor terminated	PRICE SENSITIVE	04/10/11	25.4KB	Share
1AI	Cleansing Statement		05/09/11	20.3KB	Share
1AI	Appendix 3B		05/09/11	69.08KB	Share
1AI	Preliminary Final Report	PRICE SENSITIVE	25/08/11	762.76KB	Share
1AI	First Argentina Patients Implanted	PRICE SENSITIVE	22/08/11	35.05KB	Share
1AI	Cleansing Statement		02/08/11	20.22KB	Share

1AIResponse to ASX Aware Query
04/12/13	PRICE SENSITIVE	155.84KB	Share
1AINTCELL clinical trial - Further patients approved
25/11/13	PRICE SENSITIVE	94.64KB	Share
1AIResults of Annual General Meeting
19/11/13		25.19KB	Share
1AIManaging Director's Presentation to AGM
19/11/13		1.73MB	Share
1AIChairman's Address to Shareholders
19/11/13		149.37KB	Share
1AISaftey and efficacy findings of DIA 09 study of DIABECELL
01/11/13	PRICE SENSITIVE	291.91KB	Share
1AIAppendix 4C - quarterly
30/10/13	PRICE SENSITIVE	493.4KB	Share
1AIAustralia Biotech Invest 2013
28/10/13		1.42MB	Share
1AIAnnual Report to shareholders
15/10/13		3.68MB	Share
1AINotice of Annual General Meeting/Proxy Form
15/10/13		96.2KB	Share
1AIFirst patient successfully implanted with NTCELL
20/09/13	PRICE SENSITIVE	148.65KB	Share
1AIPublication of pre-clinical trial of NTCELL in Parkinson's
16/09/13	PRICE SENSITIVE	27.62KB	Share
1AIAppendix 4E and Financial Statements
30/08/13	PRICE SENSITIVE	648.48KB	Share
1AILCT Announces Change in Regulatory Strategy
29/08/13		34.2KB	Share
1AIPreliminary Internal Review of Dia12 Study
27/08/13	PRICE SENSITIVE	59.15KB	Share
1AIChange of Director's Interest Notice
01/08/13		68.56KB	Share
1AIAppendix 4C - quarterly
31/07/13	PRICE SENSITIVE	114.03KB	Share
1AIChange of Share Registry
08/07/13		27.91KB	Share
1AIChange of Director's Interest Notice
29/05/13		69.91KB	Share
1AIOpen Briefing LCT Clinical Trials Update
09/05/13		153.52KB	Share
1AIAppendix 4C - quarterly
29/04/13	PRICE SENSITIVE	118.77KB	Share
1AICEO on Strategy - Audio Interview
21/03/13		98.84KB	Share
1AIOpen Briefing - CEO on Strategy
21/03/13		274.96KB	Share
1AILiving Cell Technologies Awarded NZBIO Company of the Year
20/03/13		171.27KB	Share
1AIAnnouncement on Half-Year Report
27/02/13		28.51KB	Share
1AIAppendix 4D and Half-Year Accounts
27/02/13	PRICE SENSITIVE	223.86KB	Share
1AIChange of Director's Interest Notice
12/02/13		68.61KB	Share
1AIAppendix 4C - quarterly
30/01/13	PRICE SENSITIVE	66.79KB	Share
1AIChange of Director's Interest Notice
24/01/13		33.32KB	Share
1AIOpen Briefing interview with MD and CEO Andrea Grant
17/12/12		238.76KB	Share
1AILCT & Otsuka to co-develop NTCELL for Parkinson's Disease
17/12/12	PRICE SENSITIVE	119.44KB	Share
1AILCT appoints Chief Science and Medical Officer
10/12/12		46.6KB	Share
1AILCT starts DIABECELL Phase IIb trial in Argentina
22/11/12		44.04KB	Share
1AIStrong interim results in Argentinian DIABECELL trial
22/11/12	PRICE SENSITIVE	50.37KB	Share
1AIAlteration to issued capital
20/11/12		76.79KB	Share
1AIInitial Director's Interest Notice
19/11/12		28.43KB	Share
1AIResults of 2012 Annual General Meeting
16/11/12		27.38KB	Share
1AIAGM Presentation
16/11/12		822.76KB	Share
1AIChairman's Address to the 2012 Annual General Meeting
16/11/12		39.99KB	Share
1AILCT CEO Dr Andrea Grant appointed Managing Director
16/11/12	PRICE SENSITIVE	41.42KB	Share
1AIEthical approval for LCT's NTCELL Phase I trial
16/11/12	PRICE SENSITIVE	40.08KB	Share
1AIChange of Director's Interest Notice
05/11/12		68.68KB	Share
1AISix reasons to invest in LCT
02/11/12		3.88MB	Share
1AIAppendix 4C - quarterly
30/10/12	PRICE SENSITIVE	98.21KB	Share
1AIAnnual Report to shareholders
15/10/12		3.11MB	Share
1AINotice of Annual General Meeting/Proxy Form
15/10/12		91.73KB	Share
1AIAuthorisation of Ph1 trial of NTCell in Parkinsons Disease
04/10/12	PRICE SENSITIVE	25.74KB	Share
1AIForm 492
03/10/12		82.16KB	Share
1AIChange of Director's Interest Notice
28/09/12		68.57KB	Share
1AILCT announces positive DIABECELL Phase I/IIa trial
26/09/12	PRICE SENSITIVE	1.83MB	Share
1AIPreliminary Final Report for the year ended 30 June 2012
29/08/12	PRICE SENSITIVE	758.29KB	Share
1AIChange of Director's Interest Notice
17/08/12		68.71KB	Share
1AIChange of Director's Interest Notice
06/08/12		67.23KB	Share
1AIChange of Director's Interest Notice
24/07/12		68.59KB	Share
1AIAppendix 4C - quarterly
23/07/12	PRICE SENSITIVE	100.63KB	Share
1AIChange of Director's Interest Notice
06/06/12		67.04KB	Share
1AILCT restructures for next stage of growth
01/06/12		202.53KB	Share
1AILCT's DIABECELL trial extension approved
17/05/12	PRICE SENSITIVE	42.18KB	Share
1AIChange of Director's Interest Notice
04/05/12		67.68KB	Share
1AICleansing Statement
03/05/12		20.22KB	Share
1AIAppendix 3B
03/05/12		68.75KB	Share
1AILCT's Share Purchase Plan successful
01/05/12		25.85KB	Share
1AIAppendix 4C - quarterly
30/04/12	PRICE SENSITIVE	56.65KB	Share
1AIDr Barry Snow to lead Parkinson's trial for LCT
17/04/12		32.69KB	Share
1AIShare Purchase Plan documents mailed to Shareholders
30/03/12		119.8KB	Share
1AILCT Presents Novel Parkinson's Disease Treatment Results
21/03/12	PRICE SENSITIVE	27.76KB	Share
1AILCT announces Share Purchase Plan
20/03/12	PRICE SENSITIVE	30.32KB	Share
1AILCT granted E.U. Patent for tissue engineering
28/02/12	PRICE SENSITIVE	26.18KB	Share
1AILCT completes pre-clinical studies of NTCELL in Parkinson's
28/02/12	PRICE SENSITIVE	27.51KB	Share
1AIHalf Yearly Report and Accounts
28/02/12	PRICE SENSITIVE	715.61KB	Share
1AIPrice query response
16/02/12	PRICE SENSITIVE	61.79KB	Share
1AILCT granted USA Patent for Auckland Island Pigs
02/02/12	PRICE SENSITIVE	27.94KB	Share
1AIChange in substantial holding
30/01/12		433.11KB	Share
1AIBecoming a substantial holder
30/01/12		431.98KB	Share
1AIAppendix 4C - quarterly
27/01/12	PRICE SENSITIVE	64.43KB	Share
1AILCT appoints Chief Executive
28/12/11	PRICE SENSITIVE	25.37KB	Share
1AIChange of Director's Interest Notice
13/12/11		69.49KB	Share
1AIChange of Director's Interest Notice
13/12/11		69.25KB	Share
1AIChange of Director's Interest Notice
13/12/11		69.17KB	Share
1AIChange of Director's Interest Notice
05/12/11		67.29KB	Share
1AIAmended AGM Poll Result
30/11/11		29.23KB	Share
1AIResults of the 2011 Annual General Meeting
28/11/11		50.74KB	Share
1AICEO's Presentation to the 2011 AGM
28/11/11		137.78KB	Share
1AIChairmans Address to the 2011 AGM
28/11/11		53.96KB	Share
1AIChange of Director's Interest Notice
24/11/11		68.66KB	Share
1AIChange of Director's Interest Notice
18/11/11		67.22KB	Share
1AIChange of Director's Interest Notice
04/11/11		68.53KB	Share
1AISettlement of $A50 million JV to commercialise DIABECELL
02/11/11	PRICE SENSITIVE	78.08KB	Share
1AIAnnual Report to shareholders
28/10/11		3.11MB	Share
1AINotice of Annual General Meeting/Proxy Form
28/10/11		139.69KB	Share
1AIAppendix 4C - quarterly
28/10/11	PRICE SENSITIVE	368.17KB	Share
1AIOtsuka commits $A25 million to JV with LCT
19/10/11	PRICE SENSITIVE	36.51KB	Share
1AICleansing Statement
11/10/11		20.82KB	Share
1AIAppendix 3B
11/10/11		70.95KB	Share
1AIResearch collaboration with Centocor terminated
04/10/11	PRICE SENSITIVE	25.4KB	Share
1AICleansing Statement
05/09/11		20.3KB	Share
1AIAppendix 3B
05/09/11		69.08KB	Share
1AIPreliminary Final Report
25/08/11	PRICE SENSITIVE	762.76KB	Share
1AIFirst Argentina Patients Implanted
22/08/11	PRICE SENSITIVE	35.05KB	Share
1AICleansing Statement
02/08/11		20.22KB	Share

REFRESH

First 3 4 5 6 7

(20min delay)
Last 1.1¢		Change 0.000(0.00%)		Mkt cap ! $18.56M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
7	1853094	1.1¢

Sellers (Offers)

Price($)	Vol.	No.
1.2¢	1078999	5

View Market Depth

No.	Vol.	Price($)
7	1853094	0.011
10	4684067	0.010
14	7982896	0.009
7	967959	0.008
7	6280009	0.007

Price($)	Vol.	No.
0.012	1078999	5
0.013	3093333	5
0.014	1522818	4
0.015	699995	3
0.016	1394000	2

Last trade - 16.12pm 29/05/2024 (20 minute delay)


Last 1.1¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
1.1¢	1.1¢	1.1¢	898966
Last updated 13.12pm 29/05/2024 ?

1AI (ASX) Chart

Day chart unavailable

ALGORAE PHARMACEUTICALS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available